Table 1 General information of the transplanted patients studied

Donor* n(%)

Live (%)

5 (14.7)

4 (17.4)

1 (9.1)

Deceased (%)

29 (85.3)

19 (82.6)

10 (90.9)

Age average average of years (range)

10.4 (1–17)

9.6 (1–17)

13.3 (7–16)

Cytomegalovirus IgG Pretransplant serology. (n = 32)

29 (90.6)

19 (82.6)

10 (90.9)

Epstein Barr Virus IgG Pretransplant serology. (n = 32)

29 (90.6)

20 (87.0)

9 (81.8)

Herpes Simplex Virus IgG Pretransplant serology. (n = 32)

25 (78.1)

17 (73.9)

8 (72.7)

Immunosuppression regimen (%)

Prednisone

23 (100)

Prednisone

11 (100)

Cyclosporine (Cs)

13 (56.5)

Cs

7 (63.6)

or Tacrolimus

11 (47.8)

or Tacrolimus

2 (8.7)

Mycophenolatemofetil (MMF)

21 (91.3)

If Cs then was indicated MMF

7 (63.6)

Basiliximab

3(13.0)

Basiliximab

5 (45.5)

or Thimogam

4 (36.4)

Antiviral prophylaxis (time)

Ganciclovir/valganciclovir (1 month)

Ganciclovir/valganciclovir (3 months)

Aciclovir (for two months after Ganciclovir or valganciclovir prophylaxis)

Graft loss

4 (11.8)

1 (4.3)

3 (27.3)

Died

5 (14.7)

3 (13.0)

2 (18.2)

Successful transplant

25 (73.5)

19 (82.6)

6 (54.5)

Samples analyzed {serum/urine}

578 {289/289}

426** {213/213}

152*** {76/76}